ArticleAnnals of medicine and surgery (2012)2026
Circulating microRNAs in post myocardial infarction remodeling: toward precision cardiology.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MicroRNAs in Cardiovascular Diseases: Molecular Networks of Cellular Homeostasis, Inflammation, and Pathological Remodeling.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-myocardial infarction (MI) ventricular remodeling is a major cause of heart failure, despite advances in revascularization and pharmacotherapy. Circulating microRNAs (miRNAs) are emerging as biomarkers for risk stratification and therapeutic targeting. This letter reviews their role in apoptosis, inflammation, and fibrosis, highlights studies from Europe, Asia, and North America, and discusses technological advances, including exosome-based miRNA panels and machine learning models. Limitations include analytical variability, limited geographic representation, and lack of integration into clinical care. Recommendations include standardizing methods, conducting large international studies, and developing actionable miRNA algorithms. Integrating miRNA profiling into post-MI care has the potential to improve risk assessment, personalize therapy, and reduce the burden of heart failure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.